News
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Eli Lilly stock soared Thursday after the pharmaceutical giant said its new weight-loss pill had cleared a late-stage ...
Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
US-based pharmaceutical company Eli Lilly on Thursday announced that its experimental oral GLP-1 pill, named orforglipron, ...
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...
Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...
Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...
3hon MSN
Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top ...
Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its ...
Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results